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1. Introduction
End-stage renal disease patients, particularly those treated with hemodialysis (HD), suffer
from complex hemostatic disorders. Patients with uremia may experience two opposite he‐
mostatic complications: bleeding diathesis and thrombotic tendencies. Bleeding diathesis in
uremic patients is primarily seen due to abnormalities in primary hemostasis, particularly
platelet function disorder and impairment of the platelet-wall interaction. Anemia, abnor‐
mal nitric oxide production and some drugs employed also contribute to bleeding diathesis.
In addition to bleeding diathesis, thrombotic complications are also frequently seen in ure‐
mic patients. Thrombotic complications play a significant role in cardiovascular events, the
main cause of mortality in this patient group. Thrombotic hemostatic changes include in‐
creased platelet aggregability, increased plasma fibrinogen, factor VIII:C and vWF levels, a
decrease in protein C and protein S anticoagulant activity, changes in fibrinolytic system ac‐
tivity and a rise in plasma lipoprotein and homocysteine levels.
In addition to hemostatic changes caused by uremia in the HD patient group, HD therapy
itself leads to various hemostatic changes. These include coagulation cascade activation as a
result of contact between the dialysis membrane and blood elements, the effect of anticoagu‐
lants used to prevent coagulation developing due to this cascade activation and a decrease
in the negative effects on platelet functions of middle molecule uremic toxins, thought to be
eliminated during HD.
Both hemorrhagic and thrombotic changes in this patient group can give rise to life-threat‐
ening consequences. For that reason, research is still continuing into identification and treat‐
ment of hemostatic abnormalities in this patient group. Here, we shall be discussing the
pathogenesis and treatment of hemorrhagic and thrombotic complications in the light of
new research.
© 2013 Özkan and Ulusoy; licensee InTech. This is an open access article distributed under the terms of the
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2. Normal hemostasis
A knowledge of normal hemostasis is needed in order to understand hemostatic disorders
in uremic patients. The normal hemostatic process establishes blood viscosity inside the ves‐
sel and rapid plaque formation as a result of vascular injury. Hemostasis consists of three
phases; primary hemostasis, coagulation and fibrinolysis (Galbusera et al., 2009). Platelets
assume the main role in primary hemostasis. Under normal conditions, it prevents vascular
endothelium platelet aggregation and adhesion. In the event of vascular injury, platelet-
mediated hemostatic plaque formation begins (Stassen et al., 2004). Two main platelet recep‐
tors, glycoprotein Ib (GPIb) and activation-dependent glycoprotein IIb–IIIa (GPIIb–IIIa)
complex, and the adhesion molecule von Willebrand factor (VWF) and fibrinogen are in‐
volved in the adhesion process in hemostatic plaque formation. Various modifications take
place in the platelets after the adhesion phase, and molecules assisting platelet activation
and adhesion, such as ADP, serotonin, epinephrine, fibrinogen, thromboxane and VWF, are
released from the platelet granules (Ruggeri et al., 2003). The coagulation phase consists of
intrinsic and extrinsic coagulation pathways. A number of coagulation proteins are involved
in these coagulation pathways, including Tissue Factor (TF), and factors VII, IX, X, V, VIII,
XI and XIII. Natural inhibitors of the coagulation cascade are protein C, Tissue factor (TF)
pathway inhibitor and antithrombin III (Stassen et al., 2004). The fibrinolytic system leads to
plasmin-mediated dissolution of fibrin. Molecules serving in this system are the plasmino‐
gen activator inhibitors PAI-1 and PAI-2, the plasmin inhibitor alpha-1-antiplasmin, al‐
pha-2-macroglobulin and thrombin activatable fibrinolysis inhibitor (TAFI) (Fay et al., 2007).
3. Bleeding diathesis in uremic patients
The relation between uremia and bleeding diathesis has been known for many years. Ure‐
mic patients used to be lost from bleeding from vital organs. Despite today’s improvement
in anemia with modern HD techniques and erythropoietin therapy, bleeding diathesis con‐
tinues to represent a significant problem. There may be serious, life-threatening bleeding,
and surgical procedures may be delayed or not performed at all out of concern over bleed‐
ing diathesis. This causes a rise in patient morbidity. The most common cause of uremic
bleeding diathesis is impaired primary hemostasis. The most frequent complications seen as
a reflection of primary hemostasis disorders are petechiae, purpura, and bleeding in the ar‐
teriovenous fistula puncture site and regions where the HD catheter is inserted (Galbusera
et al., 2009; Remuzzi et al., 1989). In addition, bleeding in vital organs may also be seen in
uremia, leading to less frequently observed but fatal complications. In HD patients in partic‐
ular, various HD therapy-related factors mean that bleeding complications to be seen more
frequently. Although various rates have been citied in HD patients in different publications,
the bleeding diathesis rate is around 10%-15%, and bleeding-associated morbidity around
15% (Davenport et al., 1994, Martin et al., 1994; van de Wetering et al., 1996). Gastrointesti‐
nal (GIS) bleeding, particularly upper GIS bleeding, is seen in one third of uremic patients
(Galbusera et al., 2009). Kutsumi et al. showed that 17% of patients presenting to the emer‐
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gency department with GIS bleeding received HD therapy (Kutsumi et al., 1998). Other ex‐
amples of vital organ bleeding include hemorrhagic stroke, subdural hematoma,
spontaneous retroperitoneal hemorrhage, hepatic subcapsular hematoma intraocular hem‐
orrhage and hemorrhagic pericarditis leading to cardiac tamponade (Galbusera et al., 2009;
Remuzzi, 1989). Of these, hemorrhagic stroke and subdural hematoma are widely observed
in HD patients. Incidence of hemorrhagic stroke is 5-10 times greater than in the normal
population. (Seliger et al., 2003; Toyoda et al., 2005), while that of subdural hematoma has
been put at 20 times greater. Mortality in this patient group has been determined at above
40% (Power et al., 2010). van de Wetering et al. observed 48 hemorrhagic complications in 78
HD patients. Forty of the patients with hemorrhagic complications had major bleeding and
8 minor bleeding. Six of the 40 major hemorrhages were intra-abdominal, 18 involved bleed‐
ing around the catheter, 3 were GIS bleeding, 12 were oronasopharyngeal and 1 intracere‐
bral. One intracerebral case, 1 intra-abdominal case and 1 with gastrointestinal bleeding
died (van de Wetering et al., 1996). As seen in all these studies, a not inconsiderable level of
hemorrhagic complications with high mortality is seen in HD patients. It is therefore impor‐
tant to understand the pathogenesis of and treatment approaches toward bleeding diathesis
in the HD patient group. While bleeding diathesis in HD patients is associated with uremia-
related factors, HD therapy itself also creates a tendency to bleeding.
3.1. The pathogenesis of uremia-associated bleeding diathesis
Predisposition to bleeding in uremic patients has been known for years. While the patho‐
genesis of bleeding diathesis is not fully established, multifactorial causes are thought to be
responsible. The most important of these factors are structural and functional defects in pla‐
telets. Other factors are abnormal platelet-vessel wall interaction, anemia, abnormal Nitric
oxide (NO) production, drug use and HD therapy itself.
3.1.1. Platelet dysfunction
3.1.1.1. Thrombocytopenia
Moderate level platelet function disorder not sufficient to cause life-threatening bleeding is
frequently seen in uremic patients (Galbusera et al., 2009). The cause of thrombocytopenia is
generally decreased platelet production or an increase in consumption (Boccardo et al., 2004;
Panicucci et al., 1983). Thrombocytopenia may be related to HD therapy itself or develop
due to primary renal disease or various accompanying comorbid conditions. These condi‐
tions include systemic lupus erythematosus, thrombotic thrombocytopenic purpura, hemo‐
lytic uremic syndrome and disseminated intravascular coagulation (Barbour et al., 2012;
Boccardo et al., 2004; Loirat et al., 2012). HD-related thrombocytopenia may be related to the
membrane and anticoagulant used in dialysis therapy. Studies investigating the effect of HD
on platelet numbers have generally looked at platelet numbers 15-30 min before HD and af‐
ter HD (Daugirdas & Bernardo, 2012). Studies investigating the effect of type of HD mem‐
brane on platelet number have shown that greater thrombocytopenia develops in non-
biocompatible cellulose membranes compared to biocompatible synthetic polymer
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membranes. Thrombocytopenia observed in non-biocompatible membranes has been associ‐
ated with complement activation (Gutierrez et al., 1994; Hoenich et al., 1997; Verbeelen et al.,
1991). Few studies have investigated the effect of membrane sterilization technique on plate‐
let number. One such study, by Miller et al. analyzed the biocompatibility of the high-flux
membrane steam sterilized F60S and ethylene oxide sterilized F60 and the low-flux mem‐
brane ethylene oxide sterilized F6, in other words, their effect on platelet and leukocyte
numbers. The three different membranes had no different effects on platelet numbers, while
the steam-sterilized membrane was shown to reduce leukocyte numbers less (Müller et al.,
1998). Another effect of HD therapy on platelet number concerns the heparin used during
therapy. Because of its low cost and short half-life, heparin is a frequently used anticoagu‐
lant in HD therapy. However, heparin-induced thrombocytopenia (HIT) is a complication
that may limit its use and cause mortality. HIT is classified into types I and II. Type-I HIT is
a widely seen form. It arises as the result of a direct reaction between heparin and thrombo‐
cytes. There is generally a slight fall in platelet numbers soon after heparin administration,
and platelet numbers return to normal despite repeated administrations of heparin. Type-II
HIT is less common, with an incidence of between 0.5% and 5% (Jang & Hursting, 2005). Eti‐
ology is attributed to platelet factor 4 and antibodies developing against heparin complex
(Suranyi & Chow, 2010; Visentin et al., 1994). HIT generally appears with the development
of thrombocytopenia, thrombosis, skin necrosis and gangrene accompanied by acute sys‐
temic reactions 5-30 min after administration of bolus unfractionated heparin (Syed & Reilly,
2009). HIT diagnosis is established by scoring the following criteria: thrombocytopenia ap‐
pearing 5-10 days after commencement of heparin therapy, the presence of any thrombotic
event, a normal platelet number before heparin, a 50% fall in platelet numbers compared to
basal values in the absence of any other cause of platelet decrease and platelet numbers re‐
turning to normal when heparin therapy is stopped (Warkentin, 2004). The first procedure
in treatment is cessation of heparin until HIT antibody results are obtained and the use of
alternative anticoagulant methods to heparin. The use of warfarin as an alternative anticoa‐
gulant until platelet numbers return to normal is not recommended (Syed & Reilly, 2009).
Saline flush, citrate anticoagulation, the direct antithrombin inhibitors lepirudin and arga‐
troban or the Factor Xa inhibitor danaparoid can be used in heparin-free dialysis (Matsuo &
Wanaka, 2008, Syed & Reilly, 2009). In conclusion, in the light of current knowledge, gener‐
ally, although uremia and HD-associated thrombocyte numbers may decline slightly, no fall
in platelet numbers that might cause fatal bleeding is observed in association with uremia
itself or in association with HD therapy (excluding HIT2).
3.1.1.2. Platelet function disorder
3.1.1.2.1. Structural and functional platelet disorder
Structural and functional disorders have long been known in uremic patients. One structural
impairment is a decrease in mean platelet volume, and this contributes to bleeding diathesis
by leading to a decrease in platelet mass (Galbusera et al., 2009; Michalak et al., 1991). There
are three main types or granule in platelets; dense granules, α granules and lysosomes (Ka‐
plan & Owen., 1986). Various substances in these granules are involved in the hemostatic
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process by being released from platelets with activation. In uremic patients, both the content
of these granules and defects in secretion during platelet activation contribute to bleeding dia‐
thesis. There are various studies of platelet granule content in uremic patients. Eknoyan et al.
showed that a low level of adenosine diphosphate (ADP) and serotonin in chronic kidney dis‐
ease patients parallels platelets’ functional defects, and that these defects can be reversed with
hemodialysis or transplantation (Eknoyan and Brown., 1981). Di Minno et al. determined a
low platelet ADP level in uremic patients compared to normal individuals, and a decrease in
thrombin-stimulated thromboxane B2 and adenosine triphosphate secretion (Di Minno et al.,
1985). Vlachoyannis et al. determined a higher cyclic-AMP level in uremic patients compared
to healthy individuals (Vlachoyannis & Schoeppe., 1982). There is a rise in cyclic-GMP (c-
GMP) in uremic patients. The rise in c-GMP level is associated with increased production of
NO, produced by platelets (Noris et al., 1993). A rise in platelet Ca content and abnormal Ca
release as a response to stimuli is another structural defect (Gura et al., 1982; Ware et al., 1989).
There are contradictory findings regarding defective arachidonic acid in uremic platelets
(Boccardo et al., 2004). Remuzzi et al. reported defective arachidonic acid metabolism in ure‐
mic platelets and a decrease in thromboxane A2 production as a reflection of this (Remuzzi et
al., 1983). Bloom et al. reported no cyclooxygenase defect in uremic patients, but determined a
decrease in thrombin-stimulated thromboxane synthesis (Bloom et al., 1986). These structural
and functional defects in uremic patients contribute to impairment in adhesion and aggrega‐
tion and facilitate bleeding diathesis. In addition to these structural and functional defects,
various uremic toxins are known to lead to platelet aggregation defect. The uremic toxins gua‐
nidosuccinic acid and phenolic acid lead to platelet aggregation defect by inhibiting ADP-in‐
duced platelet aggregation (Hedges et al., 2007).
3.1.1.2.2. Platelet-vessel wall interaction defect
Platelet-vessel wall interaction defect is one of the significant causes of bleeding diathesis, in
addition to platelet morphology and function disorder. As discussed in the section on nor‐
mal hemostasis, defective platelet adhesion to the vascular endothelium is mediated by two
important proteins; fibrinogen and von Willebrand factor (vWF). Additionally, two impor‐
tant proteins on the platelet surface, GP Ib (vWF receptor) and activation-dependent GPIIb–
IIIa complex (fibrinogen receptor), are also involved in adhesion. Platelet glycoprotein (GP)
content is divided into the membrane and intracellular component. Studies of uremic pa‐
tients have produced different results regarding GP content (Moal et al., 2003). Nomura et
al. determined decreased GP Ib expression and normal GPIIb-IIIa expression in uremic pa‐
tients (Nomura et al., 1994). In complete contrast, Sreedhara et al. determined normal GP Ib
expression and a decrease in GPIIb–IIIa expression (Sreedhara et al., 1996). Salvati et al. de‐
termined low GP Ib expression and high GPIIb–IIIa expression (Salvati et al., 2001). Moal et
al. determined low GP Ib expression in platelets at rest. They also reported higher GP Ib ex‐
pression in stimulated platelets in the HD patient group compared to the control and CKD
groups, while GPIIb–IIIa expression was lower in the CKD and HD patients compared to
the controls (Moal et al., 2003). We think this may be attributed to the technique for measur‐
ing these differences in results, whether the patient group is pre-dialysis or dialysis, if dialy‐
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sis, then whether it is HD or Peritoneal dialysis (PD) and when blood specimen is collected
(before or after HD). However, the majority of studies suggest that these two platelet GPs
decrease in uremic patients or that there is a decrease in response to stimulation. This leads
to platelet-wall interaction defect and bleeding diathesis.
vWF is one of the main important proteins in platelet adhesion. For that reason, there have
been many studies on both vWF level and function in uremic patients. However, these have
produced controversial results in terms of both levels and functions. One such study was that
by Zwaginga et al., which showed that platelet adhesion defect was not associated with ab‐
normal vWF (Zwaginga et al., 1990). Escolar et al. reported platelet adhesion defect in uremic
patients and that the defect may stem from defective interaction between vWF and the recep‐
tor (Escolar et al., 1990). Despite these conflicting results, the fact that no response is obtained
to cryoprecipitate and desmessoprin in uremic bleeding diathesis suggests defective vWF in‐
volvement (Boccardo et al., 2004; Galbusera et al., 2009). vWF defect in uremia arises because
of reduced interaction with GPIIb–IIIa receptor or reduced expression of this receptor (Mohri
et al., 1988). Defective vWF GPIIb–IIIa receptor interaction reduces TXA2 and ADP produc‐
tion by leading to defects in phosphatidylinositol bisphosphate breakdown and cytosolic cal‐
cium concentration. As a result, it leads to impaired adhesion (Hedges, 2007).
3.1.2. Anemia
Anemia is known to be widely seen in chronic kidney failure patients and to lead to morbid‐
ity and mortality. The most important reason why it leads to morbidity and mortality stems
from its negative effect on myocardial functions. Another negative effect of anemia is that it
contributes to bleeding diathesis. It is thought to do this in two ways. The first is that under
normal conditions in a non-anemic individual the flow of formed elements of blood inside
the vessel is regular. Therefore, in the event of injury, in order for the platelets to be quickly
able to form a clot, they act in the periphery near the vascular endothelium. In anemic indi‐
viduals, however, this rheological order is defective. And this leads to bleeding diathesis
(Hedges et al., 2007). Another reason is that erythrocytes release ADP and TxA2. But this se‐
cretion decreases in anemic individuals. Decreased levels of ADP and TxA2 lead to a reduc‐
tion in platelet aggregation (Valles et al., 1991). Another mechanism concentrated on is the
effect of anemia on NO. Erythrocytes are known to have a high affinity for NO. In anemia,
however, the NO scavenger role declines because the erythrocyte mass decreases. An in‐
crease in NO level, on the other hand, leads to a rise in cGMP level and a decline in platelet
aggregation (Martin et al., 1985, Galbusera et al., 2009). Improvement of anemia with both
blood transfusion and erythropoietin therapy reduces bleeding time. And these are findings
that support the hypothesis that anemia has an effect on bleeding diathesis (Livio et al.,
1982; Moia et al., 1987, Viganò et al., 1991).
3.1.3. Abnormal NO production
There is an accumulation of uremic toxins as well as guanidosuccinic acid in uremic patients.
Guanidosuccinic acid accumulation is associated with guanidine transfer from L-arginine to
aspartic acid. L-arginine is the most important precursor of NO. NO has a modulator effect on
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vascular tonus. In addition, NO prevents platelet adhesion to the endothelium, lowers cAMP-
mediated platelet aggregation and reduces platelet-platelet interaction by increasing cGMP
levels. (Noris & Remuzzi, 1999). The administration of inhale has led to a prolongation of
bleeding time in studies on healthy individuals (Högman et al., 1993). Abnormal NO produc‐
tion is therefore thought to contribute to bleeding diathesis in uremic patients.
3.2. Evaluation of bleeding diathesis
Evaluation of bleeding diathesis in uremia begins with the taking of a detailed history. The
presence of other systemic disease, drugs used, if renal replacement therapy is administered
whether this is HD or PD, and if HD what kind of membrane and which anticoagulant in what
doses are used must all be established. At physical examination, petechiae, purpura, epistaxis
and bleeding from the catheter or AVF puncture site, generally a reflection of platelet func‐
tion effect, may all be seen. In addition, physical examination findings secondary to GIS bleed‐
ing or  intracranial  or  subdural  bleeding may also  be  encountered.  Platelet  numbers  are
generally normal or slightly low at laboratory analysis. The most frequently used clinical find‐
ing in evaluation of uremic bleeding diathesis is bleeding time (Steiner et al., 1979).
3.3. Treatment of bleeding diathesis
3.3.1. Hemodialysis
As previously discussed, while the HD process itself facilitates bleeding diathesis, in renal
failure patients it is used as a therapeutic approach that reduces bleeding diathesis. HD’s re‐
ductive effect on bleeding diathesis comes about through the removal of uremic toxins from
the blood. More than 90 uremic toxins are known today. These are classified as small, mid‐
dle or large molecular toxins based on their molecular weight. Large and/or protein-bound
molecules in particular cannot be removed with HD techniques using classic low-flux mem‐
branes, but they can with high-flux membranes (Vanholder et al., 2005; Weissinger et al.,
2004). Daily and long-term dialysis may be needed for the removal of uremic toxins and to
reduce bleeding diathesis using traditional HD techniques (Hedges et al., 2007). Studies
have shown that dialysis therapy produces an improvement in platelet functions by remov‐
ing uremic toxins (Boccardo et al., 2004; Galbusera et al., 2009; Hedges et al., 2007). Howev‐
er, another point here that must not be forgotten is that HD therapy can lead to bleeding
diathesis, due to both membrane interaction and to the anticoagulants used. Therefore, hep‐
arin-free dialysis must be performed, especially with patients with active bleeding or who
have recently undergone major surgery. Various methods are currently applied for heparin-
free HD. These include HD using low-dose heparin, regional heparinization with prota‐
mine, intermittent saline flush, regional citrate anticoagulation, prostacyclin infusion and
other alternative techniques. Swartz et al. showed that regional heparinization had a lower
bleeding reduction effect than low-dose heparinization (Swartz & Port, 1979). However, in
another study by Swartz, a bleeding level as high as 26% was observed in patients with an
active risk of bleeding using low-dose controlled heparinization (Swartz, 1981). In addition,
there are studies showing that regional heparinization with protamine neutralization has an
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increasing effect on bleeding, probably associated with the delayed heparin effect (Hampers
et al., 1966). Nagarik et al. investigated the effects on bleeding diathesis episode of dialysis
performed with intermittent saline flush and anticoagulant dialysis in patients administered
intermittent renal replacement therapy in intensive care. They observed fewer bleeding epi‐
sodes in patients administered intermittent saline flush (Nagarik et al., 2010). Sagedal et al.
showed that intermittent saline flush did not reduce clot formation in dialyzers and intra‐
vascular coagulation in stable HD patients (Sagedal et al., 2006). Citrate has been used as an
anticoagulant for many years because of its Ca-binding effect. Several studies have shown
that citrate anticoagulant can be used safely in uremic patients with bleeding (Davies et al.,
2011; Jarraya et al., 2010 Kreuzer et al., 2010; Park et al., 2011). However, it must not be for‐
gotten that severe metabolic alkalosis may develop in patients receiving citrate anticoagula‐
tion, especially continuous renal replacement therapy (Alsabbagh et al., 2012). Additionally,
there are various difficulties and side-effects in citrate anticoagulation beyond continuous
renal replacement. Two reliable pumps are needed for citrate and Ca infusion, and these dif‐
ficulties and side-effects are that serious metabolic alkalosis and hypocalcemia may result.
Prostacyclin administration is another heparin-free dialysis technique. However, this techni‐
que is not much used, because it leads to headache, flushing and hypotension (Sagedal et al.,
2006). Because regional anticoagulation with heparin-protamine or citrate-calcium infusion
or intermittent saline flush lead to a loss of personnel time and have a number of side-ef‐
fects, new techniques are under development. One of these is the use of citrate-enriched di‐
alysate. Cheng et al. showed that citrate-enriched dialysate is more effective than
intermittent saline flush (Cheng et al., 2011). However, studies showing efficacy in patients
with bleeding are needed. Yixiong et al. showed that effective and safe anticoagulation is
provided in high-risk bleeding patients with low-dose argatroban (direct thrombin inhibi‐
tor) saline flush (Yixiong et al., 2010). Providing effective dialysis in HD patients with bleed‐
ing continues to be a major problem. Techniques permitting safe and effective HD need to
be developed with technological advances.
3.3.2. Desmopressin
Desmopressin (1-deamino-8-d-arginine vasopressin [DDAVP]) is a drug frequently used in
HD patients with bleeding diathesis. While its reductive effect on bleeding diathesis is not
fully understood, it is thought to function by increasing Factor VIII levels through release
from where it is stored and by reducing the effect of vWF on dysfunction (Prowse et al.,
1979). DDAVP’s reducing effect on bleeding time starts within 1 h and continues for 4-8 h.
Bleeding time returns to normal in 24 h (Mannucci et al., 1983; Galbusera et al., 2009).
DDAVP has been shown to effectively reduce bleeding time when administered intrave‐
nously (0.3 microg⁄kg) by the subcutaneous and intranasal routes (Mannucci et al., 1983;
Shapiro & Kelleher, 1984; Ulusoy et al.,2004; Viganò et al., 1989). One of the things that must
not be forgotten in desmopressin therapy is that efficacy may decline with increasing use,
probably in association with a decline in endothelial vWF stores (Canavese et al., 1985).
Flushing, headache and tachycardia may be observed during desmopressin use. But not at
such a level as to prevent its use in uremic bleeding diathesis.
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3.3.3. Cryoprecipitate
Cryoprecipitate is a blood product rich in factor VII, vWF and fibrinogen. Use takes the form
of 10 bags of American-Red-Cross-prepared cryoprecipitate infusion in 30 min. Its effect be‐
gins in 4-12 h. The effect mechanism is not fully understood, though it is thought to be asso‐
ciated with its concentrated coagulation factor content (Janson et al., 1980; Triulzi et al.,
1990). Its advantage is that its effect appears early, the disadvantage that it involves a risk of
transferring transfusion-related diseases. Hypocalcemia may also develop during cryopreci‐
pitate transfusion, as with the transfusion of other blood products. Additionally, it may rare‐
ly lead to pulmonary edema and anaphylactic reaction. Factors requiring attention during
blood and blood product transfusion, must also therefore not be forgotten in cryoprecipitate
transfusion (Galbusera et al., 2009; Hedges et al., 2007; Spinella & Holcomb, 2009). Although
cryoprecipitate works very quickly, other approaches are preferred because of the risk of
transference of transfusion-related diseases.
3.3.4. Conjugated estrogen
The bleeding diathesis-reducing effect of conjugated estrogen emerged on the basis of obser‐
vational data (Liu et al., 1980). Following these observational data, the effect on uremic
bleeding diathesis began being investigated. It has been shown that use of 0.6 mg/kg ıv (4-5
days) in uremic patients lowers bleeding time (Viganò et al., 1988). Twenty-five milligrams
of oral conjugated estrogen for 3-20 days has been shown to safely reduce bleeding time
(Viganò et al., 1988). In addition, low-dose transdermal administrations two times a week
(50–100 microg ⁄ 24 h) have also been shown to effectively reduce bleeding (Sloand & Schiff.,
1995). The bleeding diathesis-reductive effect is thought to come about by preventing NO
synthesis (Zoja et al., 1991). In the light of these studies, since there is greater research into
reducing uremic bleeding diathesis, iv administration of conjugated estrogen is recommend‐
ed over the subcutaneous and transdermal routes (Hedges et al., 2006).
3.3.5. Erythropoietin
We have already discussed the effect of anemia on bleeding diathesis. Based on these data,
researchers have investigated the effect on bleeding diathesis of erythropoietin (EPO), an in‐
dispensible element in anemia treatment in chronic kidney patients. Several studies have
shown that correction of anemia with EPO therapy reduces uremic bleeding diathesis.
EPO’s bleeding diathesis-reductive effect may come about through several mechanisms. The
first of these is that the erythrocyte mass that increases with EPO therapy serves as an NO
scavenger and reduces NO’s negative effect on platelet adhesion. Another is the disappear‐
ance of blood rheology impairment brought about by anemia (Martin et al., 1985; Viganò et
al., 1991). EPO therapy is thought to reduce bleeding diathesis by increasing the number of
reticulated platelets in bone marrow, with its greater metabolic efficacy, by increasing plate‐
let aggregation and interaction with the vascular endothelium and, finally by increasing pla‐
telets’ response to stimuli (Diaz-Ricart et al., 1999; Hedges et al., 2007; Tàssies et al., 1995;
Zwaginga et al., 1991). In conclusion, anemia treatment brings about a significant improve‐
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ment in bleeding diathesis, especially Htc, at a level of 27%-32% (Galbusera et al., 2009; Vig‐
anò et al., 1991)
In conclusion, despite advances in technology, bleeding diathesis continues to be a life
threatening condition in HD patients. Although bleeding diathesis is not fully understood, it
is thought to be associated with primary hemostasis, in other words, platelet structure and
functions. Anemia should be corrected with EPO therapy and, most important of all, effec‐
tive dialysis must be performed in order to prevent bleeding diathesis in these patients.
Since its effect starts quickly, we think that the use of DDAVP will be appropriate in acute,
life-threatening bleeding; and because its effect is long-lasting, conjugated estrogen may be
used in patients without life-threatening bleeding but requiring long-term monitoring.
4. Hypercoagulability in uremia
Thrombotic complications are encountered as frequently as bleeding diathesis and are life-
threatening in uremic patients. Thrombotic complications lead to mortality giving rise to
cardiovascular events and can also cause morbidity by leading to AVF thrombosis. Under‐
standing the pathogenesis of thrombotic events in uremic patients and the treatment is
therefore of vital importance. A rise in platelet hyperactivity, adhesion and aggregation, co‐
agulation cascade activation and a decrease in fibrinolysis are held responsible in the patho‐
genesis of the thrombotic process.
4.1. Increased platelet activation, aggregation and adhesion
The findings of studies analyzing platelet activation in HD patients are inconsistent. These
inconsistent results may stem from differences in the patient population and sampling tech‐
niques or from differences in the platelet activation markers used. Various molecules ex‐
pressed on the surface of activated platelets or various substances known to be released into
plasma in the event of platelet activation are today used as platelet activation markers. Pla‐
telet surface markers are generally evaluated using flow cytometry and monoclonal anti‐
body-based measurement. CD41 is a flow cytometric marker of activation-dependent GPIIb/
IIIa receptor. PAC-1 is used to determine this receptor in its activated state. CD42b or GPIb
are used in the determination of vWF receptor. CD62P is used in the determination of p se‐
lectin found in the membrane of platelet alpha granules and given off during platelet activa‐
tion. CD63 is used similarly to CD62P in the determination of degranulation of platelet
dense granules (Daugirdas & Bernardo., 2012; Michelson, 1996). Many studies to date have
evaluated the effect of the HD procedure on platelet activation using one or more of these
markers. These studies have also evaluated the effects on activation markers of the mem‐
brane used in the HD procedure, the site of blood collection (where blood enters or leaves
the HD membrane) and time of collection. Studies showing differences depending on blood
collection site and time and that activation markers are higher in blood samples collected at
the HD membrane exit are in the majority (Aggarwal et al., 2002; Daugirdas & Bernardo.,
2012; Reverter et al., 1994;). Additionally, these studies have also shown higher platelet acti‐
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vation markers in patients using cuprophan membrane (Cases et al., 1993; Daugirdas & Ber‐
nardo., 2012; Reverter et al., 1994). Today, in addition to the analysis of platelet activation
using flow cytometry, various markers found in platelet alpha granules and released into
plasma during platelet activation are determined using ELISA. One such marker is sCD40L.
This is a transmembrane protein structurally related to the tumor necrosis factor-α (TNF α)
family. sCD40L is a form of CD40L released into plasma from the active thrombocyte sur‐
face (Henn et al., 1998). There are studies showing that sCD40L is correlated with platelet
activation in both the normal population and HD patients. In a study of 103 HD patients in
our clinic we determined a significantly higher predialysis sCD40 L level compared to
healthy individuals. There was a rise in sCD40 L level in blood specimen taken at the end of
HD, though this was not statistically significant. Our study supported the presence of plate‐
let activation independent of the HD procedure and that the procedure had an enhancing
effect on that activation (Ulusoy et al., 2012). Signal peptide-CUB (signal peptide–CUB (com‐
plement C1r/C1s, Uegf, and Bmp1)-EGF(epidermal growth factor)- domain-containing pro‐
tein 1 (SCUBE1) is a cell surface protein belonging to the SCUBE gene family. SCUBE1 has
been shown to rise in parallel to platelet activation in acute ischemic events (Tu et al., 2006).
However, the number of studies on this novel molecule is rather limited. The first of these
limited studies in the HD patient group was performed in our clinic. We determined that a
high SCUBE 1 level in HD patients, in a manner correlated with sCD40L, regarded as a pla‐
telet activation marker in HD patients. SCUBE 1 levels were significantly high in predialysis
blood specimens and exhibited a significant rise in post-dialysis specimens. Gender, blood
pressure, BUN, creatinine, hematocrit and high-sensitivity C-reactive protein (hsCRP) levels,
hemodialysis membrane surface area, amount of ultrafiltration, blood flow rate, dialysis
flow rate and carnitine use also significantly affected elevated SCUBE 1 in our study (Ulu‐
soy et al., 2012). In conclusion, there are several studies showing platelet activation in HD
patients, and it is a fact that the HD process affects this activation. Studies on the subject are
continuing today. In addition to the effect of the HD procedure on platelet activation, there
are also evaluating the effect on adhesion. Platelet adhesion during the HD procedure can
be analyzed using the level of lactate dehydrogenase (LDH) released from the platelets
(Daugirdas & Bernardo., 2012). Researchers have particularly evaluated membrane-specific
platelet adhesion using this technique. One such study analyzed platelet adhesion in differ‐
ent membrane types by investigating LDH levels, and reported the lowest adhesion in a pol‐
ysulfone membrane (Asai) (Hayama et al., 2004). In conclusion, HD therapy leads to an
increase in platelet adhesion and degranulation. There is also an increase in platelet-platelet
and platelet-leukocyte interaction during HD. For these reasons, as with uremic bleeding
diathesis, platelets primarily involved in the hemostatic phase in the hypercoagulable proc‐
ess are held responsible for function defects.
4.2. Coagulation cascade activation and a decrease in fibrinolysis
A number of coagulation abnormalities associated with the HD procedure and uremia ap‐
pear in HD patients. The effect of the HD procedure on coagulation cascade is by two
routes. The first is blood passing through blood tubing sets and dialyzers coming into con‐
tact with the foreign surface during the procedure. The second is the anticoagulation used
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during the procedure. As already discussed, a rise in platelet activation and adhesion comes
about during the passage of blood through blood tubing sets and contact with the dialyzer
during the HD procedure (Sabovic et al., 2005). The HD procedure also leads to neutrophils
adhering to the dialysis membrane and release of granular content. The most important
molecule in granular content is TF, one of the natural initiators of the coagulation cascade
(Fischer, 2007). Endothelial damage may occur in chronic kidney patients due to uremia, ele‐
vated homocysteine, oxidative stress, inflammation and a number of traditional risk factors
(HT, DM, hyperlipidemia, cigarettes, etc.). Endothelial damage or dysfunction may cause
coagulation activation by leading to a rise in TF in particular, vWF and thrombomodulin
(Gris et al., 1994; Gordge & Neild, 1991; Hergesell et al., 1993; Ishii et al., 1991) There are also
studies showing a rise in plasmin and thrombin formation in uremic patients (Mezzano et
al., 1996; Mezzano et al., 2001). The presence of endothelial damage in uremic patients has
been evaluated using various markers. These include intracellular adhesion molecule-1
(ICAM-1), thrombin–antithrombin complex (TAT), prothrombin fragment 1+2 (F1+2), plas‐
min–antiplasmin complex (PAP), fibrin degradation products (FDP), vWF and soluble
thrombomodulin (Rios et al., 2010). A great many studies have shown a rise in these mark‐
ers of endothelial dysfunction and coagulation cascade and alterations in the fibrinolytic
system in uremic patients (Rabelink et al., 1994). One such study was performed by Kushiya
et al., who demonstrated increased plasma levels of fibrinogen, plasmin-plasmin inhibitor
complex (PIC), thrombomodulin (TM), and D-dimer pre-HD and decreased plasma levels of
protein C (PC), antithrombin (AT), TAT and tissue plasminogen activator (tPA)-plasmino‐
gen activator inhibitor-I (PAI-I) complex (tPA-PAI-1 complex) (Kushiya et al., 2003). Vaziri
et al. determined a decline in coagulation activities even though Factor XII, IX, X and II lev‐
els were normal or elevated. Additionally, they determined a significant increase in hyperfi‐
brinogenemia and D-dimer, VWF, factor VII, and factor XIII antibody levels and a
pronounced decrease in antithrombin III, free protein S, plasminogen and tissue-type plas‐
minogen activator concentration in end-stage kidney failure patients (Vaziri et al., 1994). Sa‐
gripanti et al. determined TAT, fibrinopeptide A (FPA), D dimer, vWF, tumor necrosis
factor alpha (TNF), beta-thromboglobulin (beta TG) and serotonin (5HT) levels in predialy‐
sis and HD patients compared to the controls. Erdem et al. determined high F1+2, TAT, t-
PA, urokinase-plasminogen activator (u-PA), PAP, plasminogen and α2-antiplasmin and
α2-macroglobulin levels in HD patients (Erdem et al., 1996). Studies have analyzed the clini‐
cal reflections of this coagulation cascade activation and decrease in fibrinolysis. One such
determined high levels of fibrinogen, CRP, factor VIII, antiphospholipid antibody and anti‐
factor 4 platelet-heparin levels in patients with recurrent vascular access thrombosis (O'Shea
et al., 2003). Knoll et al. showed that presence of FV Leiden and increased FVIII, Lp(a) and
homocysteine levels were associated with vascular access thrombosis (Knoll et al., 2005). In
conclusion, in addition to bleeding diathesis in HD patients, a decrease in fibrinolysis and
Hypercoagulation, a diametrically opposed condition, is a fact that must not be ignored and
continue to give rise to significant morbidity and mortality.
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4.3. Treatment
As we have already discussed, in chronic kidney patients the HD procedure itself creates a
tendency to thrombus formation due to formed elements in blood making contact with a
foreign surface (blood tubing sets and dialyzers). Anticoagulant is used during HD in order
to prevent clot formation and ensure the procedure can be completed. Anticoagulant has
been used in HD for many years. Selection and dose adjustment of anticoagulant must be
based on the patient’s clinical condition. Classic unfractionated heparin (UFH) and low mo‐
lecular weight heparin (LMWH) are the most commonly preferred anticoagulant techni‐
ques. Direct thrombin inhibitor (danaparoid) can be used in some selected cases, but the cost
is very high (Fischer et al., 2007). UFH and LMWH provide effective anticoagulation in pa‐
tients with no contraindication in the HD procedure.
Thrombotic complication of vascular access is a frequently encountered condition in the HD
patient group. Thrombotic complication is more common in patients using graft as vascular
access route in particular. Studies low dose aspirin, sulfinpyrazone and ticlopidine in the
prevention of vascular access thrombosis have produced good results (Fiskerstrand et al.,
1985; Harter et al., 1979; Kaegi et al., 1975) But these drugs are not frequently used, both be‐
cause of a lack of sufficient studies and out of a concern they may increase bleeding diathe‐
sis in this patient group with a tendency to bleeding. Another important thrombotic
complication and main cause of mortality is cardiovascular thrombotic complications (myo‐
cardial infarction, cerebrovascular event). Preventive measures against these possibly fatal
thrombotic complications in the HD patient group resemble those in the normal population.
However, we think that the most important means of preventing various risk factors that
facilitate the development of cardiovascular events particular to the HD patient group (hy‐
perhomocysteinemia, inflammation, uremic toxins, Ca-P metabolism disorder) is with ade‐
quate dialysis. The provision of effective HD and that this effectiveness is being maintained
should be checked at regular intervals.
In addition, as well as the contribution of uremia in HD patients, bleeding diathesis and
thrombotic complications are associated with the HD procedure itself. Reduction of these
complications with advances in HD technology (biocompatible membranes, new anticoagu‐
lant  methods,  etc.)  will  contribute  to  a  decrease  in  mortality  and morbidity  in  HD pa‐
tients. As with complications of all kinds in HD patients, adequate dialysis plays a key role
in this area.
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